These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20971039)

  • 1. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
    Barach YS; Lee JS; Zang X
    Trends Mol Med; 2011 Jan; 17(1):47-55. PubMed ID: 20971039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell coinhibition and immunotherapy in human breast cancer.
    Janakiram M; Abadi YM; Sparano JA; Zang X
    Discov Med; 2012 Oct; 14(77):229-36. PubMed ID: 23114578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The B7 family and cancer therapy: costimulation and coinhibition.
    Zang X; Allison JP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5271-9. PubMed ID: 17875755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
    Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell costimulation and coinhibition: genetics and disease.
    Scandiuzzi L; Ghosh K; Zang X
    Discov Med; 2011 Aug; 12(63):119-28. PubMed ID: 21878189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 immunoregulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
    Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
    Schildberg FA; Klein SR; Freeman GJ; Sharpe AH
    Immunity; 2016 May; 44(5):955-72. PubMed ID: 27192563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.
    Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C
    Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 14. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
    Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
    Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of B7-CD28 costimulation in urologic malignancies.
    Thompson RH; Kwon ED; Allison JP
    Immunotherapy; 2009 Jan; 1(1):129-39. PubMed ID: 20445772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
    Leung J; Suh WK
    Immune Netw; 2014 Dec; 14(6):265-76. PubMed ID: 25550693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.